Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Circassia Pharmaceuticals ( (GB:NIOX) ) has provided an update.
NIOX Group plc has announced significant changes to its board, with Jonathan Emms taking over as Chief Executive Officer and Sarah Duncan being promoted to Chief Financial Officer following the retirement of Michael Roller. These internal promotions aim to provide stability and continuity within the executive team, which has been credited with successfully turning around the company’s fortunes since 2020.
More about Circassia Pharmaceuticals
NIOX Group plc is a medical device company specializing in the diagnosis, monitoring, and management of asthma through point-of-care solutions. Their leading product, NIOX VERO®, is widely used by healthcare professionals and clinical research organizations for respiratory studies. The company operates in 50 countries and is dedicated to enhancing asthma care globally.
YTD Price Performance: -6.35%
Average Trading Volume: 958,170
Technical Sentiment Consensus Rating: Hold
Current Market Cap: £234.5M
For detailed information about NIOX stock, go to TipRanks’ Stock Analysis page.
